Interpreting Procalcitonin In The New Cap Guidelines

Decorative image of the Sepsis Learning Lounge

Interpreting Procalcitonin In The New Cap Guidelines

SUMMARY

In this 20-minute podcast from Emergency Medicine News, Dr. David Gaieski, Associate Professor of Emergency Medicine at Jefferson University, calls attention to question number five of the new Community-acquired Guidelines (CAP). This question asks if serum procalcitonin (PCT) plus clinical judgment versus clinical judgment alone should be used to withhold initiation of antibiotic treatment. Gain valuable perspective from interviewee Dr. Daniel Feinstein, Adult Intensivist and Clinical Associate Professor of Medicine at University of North Carolina, as he applies his expertise in antibiotic stewardship and sepsis care to an insightful conversation about interpreting PCT in the new CAP guidelines.

FEATURED EXPERT

David Gaieski, MD and Daniel Feinstein, MD

LISTEN TO THE PODCAST

Two infectious disease clinicians speak about using PCT to manage antibiotic therapy and optimize stewardship efforts.

Listen time: 20 minutes

Take me there now!

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

US Solutions

VIDAS^® B•R•A•H•M•S PCT™

Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

Learn More

PUBLISHED BY

Emergency Medicine News
November 4, 2020